- Home
- SSSS vs ASMB Comparison
SSSS vs ASMB Comparison
Compare SSSS & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSSS
- ASMB
- Stock Information
- Founded
- SSSS 2010
- ASMB 2005
- Country
- SSSS United States
- ASMB United States
- Employees
- SSSS N/A
- ASMB N/A
- Industry
- SSSS Finance: Consumer Services
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- SSSS Finance
- ASMB Health Care
- Exchange
- SSSS Nasdaq
- ASMB Nasdaq
- Market Cap
- SSSS 138.2M
- ASMB 139.8M
- IPO Year
- SSSS N/A
- ASMB 2010
- Fundamental
- Price
- SSSS $8.37
- ASMB $18.75
- Analyst Decision
- SSSS Strong Buy
- ASMB Strong Buy
- Analyst Count
- SSSS 3
- ASMB 3
- Target Price
- SSSS $9.33
- ASMB $33.00
- AVG Volume (30 Days)
- SSSS 261.6K
- ASMB 43.5K
- Earning Date
- SSSS 08-06-2025
- ASMB 08-07-2025
- Dividend Yield
- SSSS 61.57%
- ASMB N/A
- EPS Growth
- SSSS N/A
- ASMB N/A
- EPS
- SSSS N/A
- ASMB N/A
- Revenue
- SSSS $3,644,430.00
- ASMB $32,154,000.00
- Revenue This Year
- SSSS $5,400.03
- ASMB $0.04
- Revenue Next Year
- SSSS N/A
- ASMB N/A
- P/E Ratio
- SSSS N/A
- ASMB N/A
- Revenue Growth
- SSSS N/A
- ASMB 148.33
- 52 Week Low
- SSSS $3.52
- ASMB $7.75
- 52 Week High
- SSSS $8.77
- ASMB $19.93
- Technical
- Relative Strength Index (RSI)
- SSSS 67.40
- ASMB 65.84
- Support Level
- SSSS $8.31
- ASMB $18.01
- Resistance Level
- SSSS $8.35
- ASMB $18.99
- Average True Range (ATR)
- SSSS 0.36
- ASMB 0.84
- MACD
- SSSS -0.02
- ASMB -0.05
- Stochastic Oscillator
- SSSS 73.42
- ASMB 84.42
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.